Aerovate Therapeutics Stock Fundamentals
| AVTE Stock | USD 2.61 0.05 1.88% |
Aerovate Therapeutics fundamentals help investors to digest information that contributes to Aerovate Therapeutics' financial success or failures. It also enables traders to predict the movement of Aerovate Stock. The fundamental analysis module provides a way to measure Aerovate Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aerovate Therapeutics stock.
At present, Aerovate Therapeutics' Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Interest Expense is expected to grow to about 2.1 M, whereas Operating Income is projected to grow to (77.3 M). Aerovate | Select Account or Indicator |
Aerovate Therapeutics Company Shares Owned By Insiders Analysis
Aerovate Therapeutics' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Aerovate Therapeutics Shares Owned By Insiders | 0.02 % |
Most of Aerovate Therapeutics' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aerovate Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 0.018% of Aerovate Therapeutics are shares owned by insiders. This is 99.88% lower than that of the Biotechnology sector and 99.87% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 99.82% higher than that of the company.
Aerovate Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Aerovate Therapeutics's current stock value. Our valuation model uses many indicators to compare Aerovate Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aerovate Therapeutics competition to find correlations between indicators driving Aerovate Therapeutics's intrinsic value. More Info.Aerovate Therapeutics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At present, Aerovate Therapeutics' Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Aerovate Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Aerovate Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aerovate Therapeutics' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aerovate Therapeutics could also be used in its relative valuation, which is a method of valuing Aerovate Therapeutics by comparing valuation metrics of similar companies.Aerovate Therapeutics is currently under evaluation in shares owned by insiders category among its peers.
Aerovate Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Aerovate Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Aerovate Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Aerovate Fundamentals
| Return On Equity | -0.82 | ||||
| Return On Asset | -0.49 | ||||
| Current Valuation | (12.83 M) | ||||
| Shares Outstanding | 28.87 M | ||||
| Shares Owned By Insiders | 0.02 % | ||||
| Shares Owned By Institutions | 99.98 % | ||||
| Number Of Shares Shorted | 549.75 K | ||||
| Price To Earning | 0.64 X | ||||
| Price To Book | 0.94 X | ||||
| EBITDA | (81.31 M) | ||||
| Net Income | (75.52 M) | ||||
| Cash And Equivalents | 151.99 M | ||||
| Cash Per Share | 6.22 X | ||||
| Total Debt | 675 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 40.85 X | ||||
| Book Value Per Share | 2.79 X | ||||
| Cash Flow From Operations | (56.78 M) | ||||
| Short Ratio | 0.36 X | ||||
| Earnings Per Share | (2.99) X | ||||
| Target Price | 2.33 | ||||
| Number Of Employees | 51 | ||||
| Beta | 1.0 | ||||
| Market Capitalization | 75.36 M | ||||
| Total Asset | 127.42 M | ||||
| Retained Earnings | (163.42 M) | ||||
| Working Capital | 106.59 M | ||||
| Net Asset | 127.42 M |
About Aerovate Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aerovate Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aerovate Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aerovate Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 906.3 K | 805.6 K | |
| Cost Of Revenue | 96 K | 49.5 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Aerovate Therapeutics is a strong investment it is important to analyze Aerovate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aerovate Therapeutics' future performance. For an informed investment choice regarding Aerovate Stock, refer to the following important reports:Check out Aerovate Therapeutics Piotroski F Score and Aerovate Therapeutics Altman Z Score analysis. For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aerovate Therapeutics. If investors know Aerovate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aerovate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.99) | Return On Assets (0.49) | Return On Equity (0.82) |
The market value of Aerovate Therapeutics is measured differently than its book value, which is the value of Aerovate that is recorded on the company's balance sheet. Investors also form their own opinion of Aerovate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aerovate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aerovate Therapeutics' market value can be influenced by many factors that don't directly affect Aerovate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aerovate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aerovate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aerovate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.